...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BioMed research international >The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis
【24h】

The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis

机译：-174g / c白细胞介素-6基因启动子多态性作为对甲氨蝶呤和类风湿性关节炎中对甲氨蝶呤和偏乐形的差异差异的差异

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. To evaluate the association of -174G/C IL-6 polymorphism with failure in therapeutic response to methotrexate (MTX) or leflunomide (LEF). This prospective, observational cohort included 96 Mexican-Mestizo patients with moderate or severe rheumatoid arthritis (RA), initiating MTX or LEF, genotyped for IL-6 -174G/C polymorphism by PCR-RFLP. Therapeutic response was strictly defined: only if patients achieved remission or low disease activity (DAS-28 < 3.2). Results. Patients with MTX or LEF had significant decrement in DAS-28 (p < 0.001); nevertheless, only 14% and 12.5% achieved DAS-28 < 3.2 at 3 and 6 months. After 6 months with any of these drugs the -174G/G genotype carriers (56%) had higher risk of therapeutic failure compared with GC (RR: 1.19, 95% CI: 1.07-1.56). By analyzing each drug separately, after 6 months with LEF, GG genotype confers higher risk of therapeutic failure than GC (RR = 1.56; 95% CI = 1.05-2.3; p = 0.003), or CC (RR = 1.83; 95% CI = 1.07-3.14; p = 0.001). This risk was also observed in the dominant model (RR = 1.33; 95% CI = 1.03-1.72; p = 0.02). Instead, in patients receiving MTX no genotype was predictor of therapeutic failure. We concluded that IL-6 -174G/G genotype confers higher risk of failure in therapeutic response to LEF in Mexicans and if confirmed in other populations this can be used as promissory genetic marker to differentiate risk of therapeutic failure to LEF.
机译：客观的。评价-174g / c IL-6多态性与治疗响应失败的关联与甲氨蝶呤（MTX）或leflunomide（LEF）的失效。这种前景，观察队员包括96名墨西哥梅斯蒂夏患者中度或严重的类风湿性关节炎（RA），发起MTX或lef，通过PCR-RFLP进行IL-6 -174g / c多态性的基因分型。严格定义治疗反应：只有在患者取得缓解或低疾病活动（DAS-28 <3.2）时。结果。患有MTX或LEF的患者在DAS-28中具有显着衰落（P <0.001）;然而，只有14％和12.5％在3和6个月内获得DAS-28 <3.2。在6个月后，任何这些药物后，-174g / g基因型载体（56％）与GC相比具有更高的治疗失败风险（RR：1.19,95％CI：1.07-1.56）。通过分别分析每种药物，在6个月后用lef，gg基因型赋予治疗失效的风险高于gc（Rr = 1.56; 95％ci = 1.05-2.3; p = 0.003）或cc（rr = 1.83; 95％ci = 1.07-3.14; p = 0.001）。在主导模型中也观察到这种风险（RR = 1.33; 95％CI = 1.03-1.72; p = 0.02）。相反，在接受MTX的患者中，没有基因型是治疗失败的预测因素。我们得出结论，IL-6 -174g / g基因型赋予墨西哥人对莱佛莱夫的治疗反应失败的风险较高，如果在其他群体中确认，这可以用作遗传遗传标记，以区分治疗失败的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号